Patents by Inventor David John Cowan

David John Cowan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds
    Patent number: 9040518
    Abstract: Compounds of Formula I and methods for treating metabolic disorders are disclosed.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: May 26, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Christopher Joseph Aquino, Jon Loren Collins, David John Cowan, Yulin Wu
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140323487
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
    Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors
    Publication number: 20140100255
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu ZHANG, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Compounds as antagonists or inverse agonists at opioid receptors
    Patent number: 8633175
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Chemical Compounds
    Publication number: 20130029938
    Abstract: Compounds of Formula I and methods for treating metabolic disorders are disclosed.
    Type: Application
    Filed: April 27, 2011
    Publication date: January 31, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Christopher Joseph Aquino, Jon Loren Collins, David John Cowan, Yulin Wu
  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS
    Publication number: 20110124559
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: August 8, 2007
    Publication date: May 26, 2011
    Applicant: Smithkline Beecham Corporation
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Heterocycle compounds
    Patent number: 7939528
    Abstract: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: May 10, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin Karl Barvian, Jason Daniel Speake, David John Cowan, Andrew Lamont Larkin, Jerzy Ryszard Szewczyk
  • Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors
    Patent number: 7834063
    Abstract: This invention relates to benzonitryl and nitrobenzyl derivatives that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. These compounds are useful, for example, in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: November 16, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Philip Stewart Turnbull, Andrew Lamont Larkin, Istvan Kaldor, Rodolfo Cadilla, David John Cowan, Eugene Lee Stewart
  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
    Publication number: 20100222345
    Abstract: This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
    Type: Application
    Filed: August 8, 2007
    Publication date: September 2, 2010
    Inventors: Caroline Jean Diaz, Curt Dale Haffner, Jason Daniel Speake, Cunyu Zhang, Wendy Yoon Mills, Paul Kenneth Spearing, David John Cowan, Gary Martin Green
  • Aniline derivatives as selective androgen receptor modulators
    Patent number: 7723385
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: May 25, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
  • ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
    Publication number: 20090163588
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: February 25, 2009
    Publication date: June 25, 2009
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
  • Aniline derivatives as selective androgen receptor modulators
    Patent number: 7514470
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, David John Cowan, Andrew Lamont Larkin, Istvan Kaldor, Eugene Lee Stewart
  • NOVEL HETEROCYCLE COMPOUNDS
    Publication number: 20090054431
    Abstract: The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.
    Type: Application
    Filed: October 12, 2006
    Publication date: February 26, 2009
    Inventors: Kevin Karl Barvian, Jason Daniel Speake, David John Cowan, Andrew Lamont Larkin, Jerzy Ryszard Szewczyk
  • Chemical Compounds
    Publication number: 20080255124
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
    Type: Application
    Filed: October 13, 2005
    Publication date: October 16, 2008
    Applicant: Smithkline Beecham Corporation
    Inventors: Philip Stewart Turnbull, Andrew Lamont Larkin, Istvan Kaldor, Rodolfo Cadilla, David John Cowan, Eugene Stewart
  • Condensed heterocyclic compounds as calcitonin agonists
    Patent number: 7189851
    Abstract: The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: March 13, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Ashok Bhandari, Eric Eugene Boros, David John Cowan, Anthony Louis Handlon, Clifton Earl Hyman, Jeffrey Alan Oplinger, Michael Howard Rabinowitz, Philip Stewart Turnbull
  • Formamide compounds as therapeutic agents
    Patent number: 6329400
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: December 11, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
  • Formamide compounds as therapeutic agents
    Patent number: 6191150
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: February 20, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
  • Formamides as therapeutic agents
    Patent number: 6172064
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof. Also described are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: January 9, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, David John Cowan, David Norman Deaton, Scott Howard Dickerson, David Harold Drewry, Michael David Gaul, Michael Joseph Luzzio, Brian Edward Marron, Michael Howard Rabinowitz